KeyBank National Association
PHAT icon

KeyBank National Association’s Phathom Pharmaceuticals PHAT Stock Holding History

KeyBank National Association’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,512
Closed -$160K – 1192
2025
Q1 		$160K Hold
25,512
– – ﹤0.01% 1125
2024
Q4 		$207K Buy
25,512
+7,469
+41% +$92.5K ﹤0.01% 1109
2024
Q3 		$326K Buy
+18,043
New +$252K ﹤0.01% 945

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KeyBank National Association's PHAT Position: Q2 2025 in Review

KeyBank National Association sold out of Phathom Pharmaceuticals (PHAT) in Q2 2025, closing a stake of 25,512 shares — an estimated $160K sold.

KeyBank National Association first reported a position in PHAT in Q3 2024 and held it in 3 quarters. The position peaked at $326K in Q3 2024. 117 funds tracked by Wall St. Rank hold PHAT as of Q2 2025.

  • KeyBank National Association reported no remaining Phathom Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • KeyBank National Association sold 25,512 Phathom Pharmaceuticals shares in Q2 2025, an estimated $160K.
  • KeyBank National Association first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • KeyBank National Association's Phathom Pharmaceuticals position peaked at $326K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2025.

Based on KeyBank National Association's 13F filing for Q2 2025, filed 4 Aug 2025.